Onfekafusp alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name

Onfekafusp alfa

DrugBank Accession Number

DB16269

Background

Onfekafusp alfa is under investigation in clinical trial NCT02938299 (Neoadjuvant L19IL2/L19TNF- Pivotal Study).

Type

Biotech

Groups

Investigational

Synonyms

Daromun component l19tnf
Fibromun
Immunoglobulin, anti-(human fibronectin ed-b domain) (synthetic human clone l19 scfv fragment) fusion protein with human tumor necrosis factor .alpha., trimer
Onfekafusp alfa

External IDs

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Recruiting	Treatment	Malignant Melanoma	1
3	Recruiting	Treatment	Soft Tissue Sarcoma	1
2	Completed	Treatment	Malignant Melanoma, Skin	1
2	Recruiting	Treatment	Basal Cell Carcinoma (BCC) / Cutaneous Squamous Cell Carcinoma	1
2	Recruiting	Treatment	Basal Cell Carcinoma (BCC) / Kaposi's Sarcoma / Keratoacanthoma of the Skin / Malignant Adnexal Tumors of the Skin (MATS) / Merkel Cell Carcinoma / Squamous Cell Carcinoma (SCC) / Tumors From Cutaneous T-cell Lymphoma (CTCL)	1
2	Recruiting	Treatment	Leiomyosarcoma (LMS)	1
2	Recruiting	Treatment	Soft Tissue Sarcoma	1
1	Active Not Recruiting	Treatment	Soft Tissue Sarcoma	1
1	Not Yet Recruiting	Treatment	High Grade Glioma: Glioblastoma (GBM)	1
1, 2	Completed	Treatment	Glioma	1

Drug created at December 15, 2020 18:17 / Updated at February 21, 2021 18:55